Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 785

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 785
---
 that it has duly caused and authorized the undersigned to sign this annual report on Form 20 -Ffiled on its behalf.

| Date May 15, 2024 |     | NLS Pharmaceutics Ltd. 
 By:                    |     | /s/ Alexander Zwyer     |
|:------------------|:----|:-----------------------|:----|:------------------------|
|                   |     |                        |     | Alexander Zwyer         |
|                   |     |                        |     | Chief Executive Officer |
|                   |     | By:                    |     | /s/ Elena Thyen-Pighin  |
|                   |     |                        |     | Elena Thyen-Pighin      |
|                   |     |                        |     | Chief Financial Officer |

Annex F-114 NLS PHARMACEUTICS LTD.
FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021 Annex F-115

NLS PHARMACEUTICS LTD.
FINANCIAL STATEMENTS

| Report of Independent Registered Public Accounting Firm (PCAOB ID 1358)                                      
 Balance Sheets as of December 31, 2023 and 2022                                                              
 Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023, 2022 and 2021         |     | Page  
 F-117 
 F-118 
 F-119 |
|:-------------------------------------------------------------------------------------------------------------|:----|:------|
| Statements of Changes in Shareholders’ Equity/(Deficit) for the Years Ended December 31, 2023, 2022 and 2021 |     | F-120 |
| Statements of Cash Flows for the Years Ended December 31, 2023, 2022 and 2021                                |     | F-121 |
| Notes to Financial Statements                                                                                |     | F-123 |

Annex F-116 Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of
NLS Pharmaceutics Ltd. Opinion on the Financial Statements We have audited the accompanying balance sheets of NLS Pharmaceutics Ltd. (the “Company”) as of December 31, 2023 and 2022, and the related statements of operations and comprehensive loss, of changes in equity and of cash flows for each of the three years in the period ended December 31, 2023, including the related notes (collectively referred to as